Popular on EntSun
- VIDCAT Launches VIDCAT ARCHIVE EDU A New Fashion Videos Streaming Portal - 122
- July Super Sale At Sunber Hair - 110
- WhatALife Music Collective announces distribution deal with Empire - 104
- Comedy Hypnotist Don Barnhart Brings Hypnomania Show To Las Vegas
- Action Termite and Pest Control Opens New Office in Blackwood, NJ
- Tobu Railway to Introduce its Latest N100 Series of Limited Express Spacia X Trains in July 2023
- Employers 4 Change The Intern Whisperer Podcast Hits Major Milestones
- BNi Building News Announces Updated Cost Escalators to Address Inflation
- Fashion Designer Nic Hyl Named Top 10 Female CEO's To Watch In 2022
- A Dream That Became a Reality by Ismail Sirdah
Similar on EntSun
- 10 Years in the Making: #LatinaGeeks Celebrates 10th Anniversary with Inaugural Inspirada Awards & Fundraising Gala
- Zonit Launches the World's Best Automatic Transfer Switch for Industrial & Commercial Applications
- What You Need to Know on "Opening an IV Therapy Clinic" Podcast Interview to Grow, Start or Expand IV Hydration Therapy Business
- Calling All Witches: WitchFest 2022 Announced in Denver Colorado
- New music from Sho Richardsin, 'The Win'
- Sharifah Hardie Launches Campaign to Raise $1.5B for Local Black Businesses
- History Making Female Football Player Takes a Stand for Global Gender Equality
- The Data Economics Company and Syzygy Publishing's Chris Ryall announces content partnership
- The Stars Align for Coffee Lovers in North Texas with Opening of Tre Stelle Coffee Co. in North Dallas
- Hamilton County Commissioner and Founder of the Cincinnati Black Music Walk of Fame, Alicia Reece, Led A Star-Studded 2nd Annual Induction Ceremony
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
EntSun News/10949369
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on August 3, 2022, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 37,250 shares of Puma common stock to six new non-executive employees.
The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying each award vesting on the first anniversary of the award's vesting commencement date, August 1, 2022, and one-sixth of the shares underlying each award vesting on each six-month anniversary of the vesting commencement date thereafter, subject to continued service. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).
More on EntSun News
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.
Contacts
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
info@pumabiotechnology.com
ir@pumabiotechnology.com
The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying each award vesting on the first anniversary of the award's vesting commencement date, August 1, 2022, and one-sixth of the shares underlying each award vesting on each six-month anniversary of the vesting commencement date thereafter, subject to continued service. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).
More on EntSun News
- Is Will Smith's Apologie Good Enough For Be Kind To HumanKind Week?
- HWS Announces Top 10 Low Cost Vacation Spots
- Eighteenth Annual 72 Hour Shootout Filmmaking Top Ten Premiere: Joyful Resistance
- Tribute to the Divas! Night on September 10th with Live! Mariachi at Argentine Club of LA!
- World's First Walkie-Talkie Bone Conduction Sport Headphones
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.
Contacts
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
info@pumabiotechnology.com
ir@pumabiotechnology.com
Filed Under: Business
0 Comments
Latest on EntSun News
- Hypnomania Comedy Hypnosis Show In Las Vegas Brings Audience Participation To An Exciting New Level
- Kinugawa Onsen Celebrates its 330th Anniversary AND Kawagoe City Celebrates its 100th Anniversary - Both with Fireworks!
- VA Center of North County Hosts It's First Annual VANC Fest; an Art, Music and Culinary Experience
- Nino X Man releases Hip-Hop Compilation titled "662 the Truth" with No Limit Forever East
- RAEN'S Hand-Crafted Sunglasses Launch In Three New Colorways
- 10 Years in the Making: #LatinaGeeks Celebrates 10th Anniversary with Inaugural Inspirada Awards & Fundraising Gala
- 3i Solutions Announces New Leadership Brings a Customer-Focused Approach
- Oh Yeah! "Rockquiem For A Wrestler" Cast Recording Heads To Digital On October 28, 2022
- Jordan Ravenhill to release NEW single "Apart Of Me"
- Indie Filmmaker's Wild Mustang Passion Project Corrals Worldwide Audience on Documentary Showcase
- Enjoy The Cleverness of 'The Mysterious Mr. Wizdom' With Summer Hill's New Release
- "Kickin' the Blues Music Festival" Planned with Iconic Artists
- Help Wanted: Oakland-Based Children Rising Seeks Volunteers to Help Students Overcome COVID-Related Learning Loss
- Alander Pulliam launched His own FM Gospel Radio Station In Los Angeles California
- E3 Forensic Platform Innovates again with Remote Cloud Collection
- New Jewish Theatre Presents World Premiere of "The Bee Play" September 8-25
- Zonit Launches the World's Best Automatic Transfer Switch for Industrial & Commercial Applications
- Podcast created by Jillian Clare inks exclusive deal with Realm
- Central Florida Zoo & Botanical Gardens announces return of train attraction
- Cannes-Premiered Two-Time Award-Winning Short to Make US Debut